Stanford physician helps shape new national guidelines for recurrent pregnancy loss

Dr. Ruth Lathi
Professor of Obstetrics and Gynecology and Director of the Recurrent Pregnancy Loss Program

May 27, 2026

Repeated miscarriages and the search for answers can be emotionally devastating for patients who desire to grow their families. New national guidelines from the American Society for Reproductive Medicine aim to change that by rethinking how recurrent pregnancy loss is defined, evaluated, and treated.

The updated committee opinion, published in Fertility and Sterility, reflects more than a decade of research into miscarriage and reproduction. Among the most significant changes: recurrent pregnancy loss is now defined as two or more pregnancy losses, rather than three, and clinicians are encouraged to begin by testing miscarriage tissue itself for chromosomal abnormalities.

Professor of Obstetrics and Gynecology and Director of the Recurrent Pregnancy Loss Program at Stanford Medicine Ruth Lathi, MD, who contributed to the updated guidance, said the field has fundamentally shifted how it approaches recurrent miscarriage.

“Historically, the workup focused primarily on investigating the parents,” Lathi explained. “But we know a majority of miscarriages are caused by de novo chromosomal or genetic problems in the pregnancy itself. By testing the miscarriage tissue first, we’re more likely to give patients answers earlier in the process.”

The new recommendations reflect growing evidence that genetic problems in the pregnancy itself are the most common problem of miscarriage and once an explanation is found it can spare patients a battery that are often non-informative and can raise anxiety about future pregnancies.

“Finding answers can reduce some of the blame and guilt patients often feel after a miscarriage,” Lathi said. “People often internalize these losses, when in many cases they are caused by random chromosomal events that were outside anyone’s control.”

Lathi said these changes were informed both by scientific evidence and by listening to patients who had experienced miscarriage firsthand. The guidelines also broaden the definition of pregnancy loss to include early miscarriages and those happening at home, rather than requiring ultrasound confirmation of a pregnancy.

“Not everyone has access to early ultrasound care or the emergency room,” she said. “Many people experience losses at home, and those experiences are real and significant. We wanted the guidelines to better reflect the realities patients are living.”

The updated framework introduces a stepwise algorithm to recurrent pregnancy loss evaluation. Rather than ordering extensive testing immediately, clinicians are encouraged to first determine whether a miscarriage was caused by a chromosomal abnormality. If the loss is chromosomally normal, additional evaluation for factors such as uterine abnormalities, antiphospholipid syndrome, thyroid disease, diabetes, or sperm DNA fragmentation may follow.

Crucially, the guidelines remind both patients and providers that unexplained recurrent loss does not preclude a healthy future pregnancy. Many patients go on to have successful pregnancies without any additional intervention.

One of the committee’s goals, Lathi said, was to help more patients receive meaningful explanations for their losses. “Historically, only about half of patients with recurrent pregnancy loss were given an identifiable cause. With this new algorithm and chromosome testing approach, we believe that between 80 and 90 percent of patients may come away with answers and, by finding answers, we can provide better care.”

The most important message to a patient experiencing a miscarriage is that this is not their fault.

Still, major gaps remain in the field, particularly around racial disparities in reproductive health.

“Black women continue to experience the worst maternal health outcomes across almost every measure, recurrent pregnancy loss included,” Lathi said. “We need more research that helps us better understand those disparities and provide more individualized care.”

Beyond the clinical recommendations, the new guidelines underscore the psychological and mental toll of miscarriage. Studies cited show that patients experiencing recurrent pregnancy loss face significantly increased risks of anxiety, depression, and post-traumatic stress.

For Lathi, improving miscarriage care is not only about better testing or treatment algorithms, but also about changing how clinicians communicate with patients. “The most important message to a patient experiencing a miscarriage is that this is not their fault,” she said.

The guidelines conclude with a call for continued research into the genetic, immune, and biological causes of recurrent miscarriage, while encouraging clinicians to ground care in evidence, compassion, and psychological support.